DK147706C - Analogifremgangsmaade til fremstilling af cycliske aminocarboxylsyrer eller farmakologisk acceptable salte deraf - Google Patents

Analogifremgangsmaade til fremstilling af cycliske aminocarboxylsyrer eller farmakologisk acceptable salte deraf

Info

Publication number
DK147706C
DK147706C DK581475A DK581475A DK147706C DK 147706 C DK147706 C DK 147706C DK 581475 A DK581475 A DK 581475A DK 581475 A DK581475 A DK 581475A DK 147706 C DK147706 C DK 147706C
Authority
DK
Denmark
Prior art keywords
analogue
preparation
acceptable salts
aminocarboxylic acids
pharmacological acceptable
Prior art date
Application number
DK581475A
Other languages
Danish (da)
English (en)
Other versions
DK147706B (da
DK581475A (da
Inventor
Gerhard Satzinger
Johannes Hartenstein
Manfred Herrmann
Wolfgang Heldt
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5934284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK147706(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of DK581475A publication Critical patent/DK581475A/da
Publication of DK147706B publication Critical patent/DK147706B/da
Application granted granted Critical
Publication of DK147706C publication Critical patent/DK147706C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK581475A 1974-12-21 1975-12-19 Analogifremgangsmaade til fremstilling af cycliske aminocarboxylsyrer eller farmakologisk acceptable salte deraf DK147706C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2460891 1974-12-21
DE2460891A DE2460891C2 (de) 1974-12-21 1974-12-21 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (3)

Publication Number Publication Date
DK581475A DK581475A (da) 1976-01-22
DK147706B DK147706B (da) 1984-11-19
DK147706C true DK147706C (da) 1985-05-13

Family

ID=5934284

Family Applications (1)

Application Number Title Priority Date Filing Date
DK581475A DK147706C (da) 1974-12-21 1975-12-19 Analogifremgangsmaade til fremstilling af cycliske aminocarboxylsyrer eller farmakologisk acceptable salte deraf

Country Status (16)

Country Link
US (1) US4024175A (de)
JP (1) JPS5324064B2 (de)
AT (1) AT340892B (de)
BE (1) BE836835A (de)
CA (1) CA1052811A (de)
CH (3) CH612665A5 (de)
DE (1) DE2460891C2 (de)
DK (1) DK147706C (de)
ES (1) ES443723A1 (de)
FI (1) FI62282C (de)
FR (1) FR2294697A1 (de)
GB (1) GB1465229A (de)
IE (1) IE42382B1 (de)
LU (1) LU74058A1 (de)
NL (1) NL181006C (de)
SE (1) SE423385B (de)

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
JPS5776189U (de) * 1980-10-28 1982-05-11
JPS6152583U (de) * 1984-09-11 1986-04-09
JPS61139881U (de) * 1985-02-21 1986-08-29
US4876279A (en) * 1986-05-05 1989-10-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
YU162789A (en) * 1988-09-01 1990-12-31 Lonza Ag 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
DE3928182A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
AU633612B2 (en) * 1989-08-25 1993-02-04 Warner-Lambert Company Improved process for cyclic amino acid anticonvulsant compounds
US5319135A (en) * 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
US5157138A (en) * 1989-11-16 1992-10-20 Pfizer, Inc. Glutaric acid derivatives and preparation thereof
GB8925933D0 (en) * 1989-11-16 1990-01-04 Pfizer Ltd Glutaric acid derivatives and preparation thereof
US5136091A (en) * 1989-11-16 1992-08-04 Lonza Ltd. Process for the production of 1-(aminomethyl) cyclohexane acetic acid
US5149870A (en) * 1989-11-16 1992-09-22 Lonza Ltd. Process for the production of 1-(aminomethyl)cyclohexane acetic acid
FI905584L (fi) * 1989-11-16 1991-05-17 Lonza Ag Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra.
US5260467A (en) * 1989-11-16 1993-11-09 Pfizer Inc. Glutaric acid derivatives and preparation thereof
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
CA2244708A1 (en) * 1996-02-07 1997-08-14 Justin S. Bryans Novel cyclic amino acids as pharmaceutical agents
IL125364A0 (en) * 1996-03-14 1999-03-12 Warner Lambert Co Novel bridged cyclic amino acids and pharmaceutical compositions containing them
PL185991B1 (pl) * 1996-03-14 2003-09-30 Warner Lambert Co Nowe podstawione cykliczne aminokwasy i kompozycja farmaceutyczna
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
AU733896B2 (en) * 1996-10-23 2001-05-31 Warner-Lambert Company Substituted gamma aminobutyric acids as pharmaceutical agents
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6255526B1 (en) 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
AU9019198A (en) 1997-08-19 1999-03-08 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU9318398A (en) 1997-10-07 1999-04-27 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
CU23048A3 (es) * 1997-10-27 2005-06-24 Warner Lambert Co Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
US6984659B2 (en) * 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
EP1475371A1 (de) 1997-12-16 2004-11-10 Warner-Lambert Company LLC 1-substituierte-1-aminomethyl-cycloalkan derivate (= gabapentin analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen
EP1400526A3 (de) 1997-12-16 2004-03-31 Warner-Lambert Company LLC (cyclo)alkyl substituierte-gamma -aminobuttersäure Derivate (=Gaba Analoga), ihre Herstellung und ihre Verwendung zur Behandlung von neurologischen Krankheiten
CA2304967C (en) 1997-12-16 2005-06-14 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
CA2309354A1 (en) * 1998-01-23 1999-07-29 Leslie Magnus-Miller Gabapentin and its derivatives for the treatment of muscular and skeletal pain
EP0974351A3 (de) * 1998-04-24 2000-12-13 Jouveinal Arzneimittel zur Vorbeugung und Behandlung von Magendarmschäden
CN100337687C (zh) * 1998-05-15 2007-09-19 沃尼尔·朗伯公司 含有γ－氨基丁酸衍生物的固体组合物及其制备方法
CN1303991C (zh) 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
ES2137137B1 (es) * 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
KR20010043831A (ko) 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 칼슘 채널의 알파2델타 서브유닛에 대한 친화력이 있는구조적으로 한정된 아미노산 화합물
ITMI981535A1 (it) * 1998-07-03 2000-01-03 Zambon Spa Processo per la preparazione di gabapentina
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
HU225502B1 (en) * 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
IT1311984B1 (it) 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
WO2000061188A1 (en) * 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US6710190B1 (en) * 1999-05-28 2004-03-23 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
JP2003500486A (ja) * 1999-05-28 2003-01-07 ワーナー−ランバート・カンパニー ３−ヘテロアリールアルキル置換ｇａｂａ類似体
HRP20020025A2 (en) * 1999-06-10 2003-12-31 Warner Lambert Co Mono- and disubstituted 3-propyl gamma-aminobutyric acids
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
CA2411787C (en) * 2000-06-16 2007-03-20 Teva Pharmaceuticals Industries Ltd. Stable gabapentin having ph within a controlled range
EP1384473A1 (de) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stabiles Gabapentin das mehr als 20 ppm Chlor enthält
CA2410867C (en) 2000-06-16 2003-12-09 Claude Singer Stable gabapentin containing more than 2o ppm of chlorine ion
ATE390133T1 (de) * 2000-06-26 2008-04-15 Warner Lambert Co Gabapentinanaloga für schlafstörungen
GB2364049A (en) * 2000-06-28 2002-01-16 Warner Lambert Co Cyclic ketones and their use in the synthesis of amino acids
DK1317426T3 (da) * 2000-09-14 2006-01-09 Gruenenthal Gmbh Betal-thio-aminosyrer
US6900192B2 (en) * 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1343805A4 (de) * 2000-10-06 2005-07-20 Xenoport Inc Von gallensäuren abgeleitete verbindungen für die bereitstellung anhaltender systemischer konzentrationen von arzneimitteln nach oraler verabreichung
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
IT1319234B1 (it) * 2000-10-23 2003-09-26 Zambon Spa Processo di preparazione di gabapentina.
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
CA2427237A1 (en) 2000-11-02 2002-05-10 Teva Pharmaceutical Industries Ltd. Improved process for production of gabapentin intermediate
EP1337271B1 (de) * 2000-11-30 2004-11-03 Pfizer Products Inc. Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren
CZ20031387A3 (cs) * 2000-11-30 2004-04-14 Pfizer Products Inc. Farmaceutický prostředek, kterým je směs agonistů gama-aminomáselné kyseliny a inhibitorů aldózreduktázy
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
JP2004524339A (ja) * 2001-03-16 2004-08-12 ソルケム イタリアーナ エス．ピー．エイ． 環状アミノ酸の調製方法
ITMI20011132A1 (it) 2001-05-29 2002-11-29 Procos Spa Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
PT1404324E (pt) * 2001-06-11 2008-03-05 Xenoport Inc Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
IL144066A0 (en) * 2001-06-28 2002-04-21 Bromine Compounds Ltd Process for the preparation of 1,1-cyclohexane diacetic monoamide
ITMI20011772A1 (it) 2001-08-10 2003-02-10 A M S A Anonima Materie Sint E Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
ATE317280T1 (de) 2001-09-03 2006-02-15 Newron Pharm Spa Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung
US6800782B2 (en) * 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
CA2474000A1 (en) * 2002-01-31 2003-08-07 Warner-Lambert Company Llc Alpha 2 delta ligands to treat tinnitus
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7026351B2 (en) * 2002-03-20 2006-04-11 Xenoport, Inc. Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
WO2003089403A1 (en) * 2002-04-16 2003-10-30 Taro Pharmaceutical Industries Ltd. Process for preparing gabapentin
CA2484891A1 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2004002462A2 (en) * 2002-06-27 2004-01-08 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
CA2395931A1 (en) * 2002-08-07 2004-02-07 Bernard Charles Sherman Solid compositions comprising gabapentin having improved stability
US7053122B2 (en) * 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092591A1 (en) * 2002-08-15 2004-05-13 Blakemore David Clive Therapeutic use of fused bicyclic or tricyclic amino acids
US20040092498A1 (en) * 2002-08-16 2004-05-13 David Blakemore Substituted glycine derivatives for use as medicaments
ITMI20022071A1 (it) * 2002-10-01 2004-04-02 Erregierre Spa Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
US7659305B2 (en) * 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
WO2004046084A1 (en) * 2002-11-18 2004-06-03 Nicholas Piramal India Limited Improved process for preparation of gabapentin
ATE439343T1 (de) * 2002-11-20 2009-08-15 Hikal Ltd Verbessertes verfahren zur zubereitung von gabalactam
AU2003297909A1 (en) * 2002-12-11 2004-06-30 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
US7060727B2 (en) * 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
EP2172197A1 (de) 2002-12-13 2010-04-07 Warner-Lambert Company LLC Octansäure Derivat zur Behandlung von Fibromyalgia und anderen Schmerzen
NZ567457A (en) 2002-12-13 2009-08-28 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
JP2006511605A (ja) * 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 線維筋痛及び他の関連障害のためのガバペンチン類縁体
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
KR100845932B1 (ko) * 2002-12-13 2008-07-11 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 관련 질환의 치료를 위한 프레가발린및 그의 유도체
GB0301143D0 (en) * 2003-01-17 2003-02-19 Amedis Pharm Ltd Compounds and their use
WO2004065361A2 (en) * 2003-01-22 2004-08-05 Warner-Lambert Company Llc Cyclopropyl beta-amino acid derivatives
WO2004078734A1 (en) * 2003-03-07 2004-09-16 Warner-Lambert Company Llc TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
WO2004093866A1 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Process for preparing phenolic acid salts of gabapentin
DE602004017166D1 (de) * 2003-03-25 2008-11-27 Kiel Lab Inc Gabapentintannat in flüssigen und/oder halbfesten dosierformen
EP1622603A4 (de) * 2003-03-25 2010-03-24 Kiel Lab Inc Phenolsäuresalze von gabapentin in festen dosierformen und anwendungsverfahren
MXPA05010515A (es) * 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
ITMI20030825A1 (it) * 2003-04-18 2004-10-19 Farchemia Srl Procedimento per la preparazione di gabapentin esente da
US7439387B2 (en) * 2003-04-21 2008-10-21 Matrix Laboratories Ltd. Process for the preparation of Gabapentin form-II
KR20060011873A (ko) * 2003-05-16 2006-02-03 화이자 프로덕츠 인코포레이티드 비정형 항정신약과 ｇａｂａ 조절제, 항경련성 약물 또는 벤조다이아제핀의 치료 혼합물
BRPI0411654A (pt) * 2003-06-19 2006-08-08 Pfizer Prod Inc preparação biocatalìtica de ácido 1-cianocicloexanoacético
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
EP1680125A1 (de) * 2003-07-02 2006-07-19 Warner-Lambert Company LLC Kombination eines allosterischen hemmers der matrix metalloproteinase 13 und eines liganden des alpha-2-delta rezeptors
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
EP1670451A4 (de) * 2003-09-11 2009-10-21 Xenoport Inc Behandlung und/oder prävention von harninkontinenz mit prodrugs von gaba-analoga
JP2007505095A (ja) * 2003-09-12 2007-03-08 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー うつ病及び不安障害の治療のためのアルファ−２−デルタリガンド及びｓｓｒｉ及び／又はｓｎｒｉを含む組み合わせ
MXPA06002789A (es) 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
WO2005027850A2 (en) * 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
KR101096480B1 (ko) * 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
ITMI20032165A1 (it) * 2003-11-11 2005-05-12 Zambon Spa Processo di preparazione di gabapentina
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
CA2553291A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
EP2172445A1 (de) * 2004-03-17 2010-04-07 Hikal Limited Cis (Z) 4-t-Butylgabapentin und seine Synthese
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
CA2567365A1 (en) * 2004-06-09 2006-01-05 Pfizer Inc. Use of reboxetine for the treatment of pain
GB0416228D0 (en) * 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
GB0419849D0 (en) * 2004-09-07 2004-10-13 Pfizer Ltd Pharmaceutical combination
SI1809271T1 (sl) * 2004-09-10 2010-10-29 Newron Pharm Spa Uporaba (R)-(halobenziloksi) benzilamino propanamidov kot selektivnih modulatorjev natrijevih in/ali kalcijevih kanalov
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
RS51298B (sr) * 2005-09-23 2010-12-31 Janssen Pharmaceutica N.V. Modulatori heksahidro-ciklooktil pirazol kanabinoida
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
CA2623745A1 (en) * 2005-09-23 2007-04-05 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
CA2623803A1 (en) 2005-09-23 2007-03-29 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EP1942879A1 (de) 2005-10-31 2008-07-16 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7526911B2 (en) * 2006-02-03 2009-05-05 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
EP1820502A1 (de) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Wirkstoffzusammensetzungen enthaltend Azolycarbinolderivate
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
BRPI0708671A2 (pt) * 2006-03-06 2011-06-07 Pfizer Prod Inc ligantes alfa-2-delta para sono não restaurador
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US8012957B2 (en) * 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7442834B2 (en) * 2006-06-12 2008-10-28 Zhejiang Chiral Medicine Chemicals Co., Ltd. Process suitable for industrial scale production of gabapentin
CN101484413B (zh) * 2006-06-30 2014-05-14 Zach系统股份公司 制备加巴喷丁的方法
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EA200970487A1 (ru) * 2006-12-08 2009-12-30 Ксенопорт, Инк. Применение пролекарств аналогов гамк для лечения заболеваний
CN102058885B (zh) 2006-12-22 2013-04-10 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
KR20090121388A (ko) * 2007-03-15 2009-11-25 썬 파마 어드밴스트 리서치 컴패니 리미티드 신규 전구약물
US20090041806A1 (en) * 2007-06-15 2009-02-12 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090062392A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched gabapentin
TW200936123A (en) * 2007-11-06 2009-09-01 Xenoport Inc Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
JP5563483B2 (ja) * 2008-01-25 2014-07-30 ゼノポート，インコーポレイティド アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
EP2116539A1 (de) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
US9192681B2 (en) 2009-02-24 2015-11-24 Nektar Therapeutics Oligomer-amino acid conjugates
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
EP2353591A1 (de) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon
EP2368872A1 (de) 2010-03-25 2011-09-28 Serichim S.r.l. Verfahren zur Herstellung von Gabapentin
EP2388005A1 (de) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie
EP2575798B1 (de) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosierungszubereitung von gaba analoga
US8431739B2 (en) 2010-06-14 2013-04-30 Divi's Laboratories, Ltd. Process for the preparation of gabapentin
BR112013000164B1 (pt) 2010-07-30 2021-11-23 Toray Industries, Inc Agente terapêutico ou agente profilático
EP2415471A1 (de) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie
JP2013216580A (ja) * 2010-08-06 2013-10-24 Kyorin Pharmaceutical Co Ltd ビシクロ［２．２．２］オクチルアミン誘導体の製造方法
EP2524694A1 (de) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes
EP2530072A1 (de) 2011-06-03 2012-12-05 Lacer, S.A. Neue Verbindungen, deren Synthese und Verwendung bei der Schmerzbehandlung
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
ITMI20131757A1 (it) 2013-10-22 2015-04-23 Zach System Spa Processo di preparazione di gabapentina
KR20160081864A (ko) 2013-11-01 2016-07-08 가부시키가이샤 도우사 고가쿠 겐큐쇼 티올기를 갖는 d-체 또는 l-체 아미노산 유도체의 제조 방법
AU2014364644A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and Sigma receptor ligands combinations
AU2014364647A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations
EP2923694B1 (de) 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Orale flüssige pharmazeutische lösung von gabapentin
UA124977C2 (uk) 2016-12-16 2021-12-22 Ідорсія Фармасьютікалз Лтд Фармацевтична комбінація, яка містить блокатор кальцієвих каналів т-типу
MX384760B (es) 2018-07-04 2025-03-14 Federico Amezcua Amezcua Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
US10399926B1 (en) 2018-08-01 2019-09-03 Divi's Laboratories Ltd. Process for the preparation of gabapentin
AU2018445164B2 (en) 2018-10-11 2025-05-29 Vifor (International) Ltd. Inositol phosphates for the treatment of ectopic calcification
CN114599397B (zh) 2019-10-25 2024-05-28 国立大学法人京都大学 Tau蛋白病的预防或治疗剂
KR20220163384A (ko) 2020-03-04 2022-12-09 플레오파마, 엘.엘.씨. 칸나비스 사용 장애를 치료하고 칸나비노이드 금단을 완화하기 위한 방법 및 조성물
EP4015494A1 (de) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Verfahren zur herstellung von löslichen salzen von inositolphosphaten
GB2625579A (en) 2022-12-21 2024-06-26 Novumgen Ltd An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same

Also Published As

Publication number Publication date
BE836835A (fr) 1976-06-18
JPS5188940A (de) 1976-08-04
FR2294697A1 (fr) 1976-07-16
DE2460891C2 (de) 1982-09-23
IE42382L (en) 1976-06-21
IE42382B1 (en) 1980-07-30
NL181006B (nl) 1987-01-02
JPS5324064B2 (de) 1978-07-18
DE2460891A1 (de) 1976-07-01
NL7514900A (nl) 1976-06-23
DK147706B (da) 1984-11-19
CH612665A5 (de) 1979-08-15
FI753613A7 (de) 1976-06-22
GB1465229A (en) 1977-02-23
DK581475A (da) 1976-01-22
NL181006C (nl) 1987-06-01
CH612666A5 (de) 1979-08-15
AT340892B (de) 1978-01-10
SE423385B (sv) 1982-05-03
CA1052811A (en) 1979-04-17
FI62282B (fi) 1982-08-31
ATA975075A (de) 1977-05-15
LU74058A1 (de) 1976-07-20
ES443723A1 (es) 1977-04-16
FR2294697B1 (de) 1978-07-28
SE7514442L (sv) 1976-06-22
US4024175A (en) 1977-05-17
AU8774175A (en) 1977-06-23
FI62282C (fi) 1982-12-10
CH612664A5 (de) 1979-08-15

Similar Documents

Publication Publication Date Title
DK147706C (da) Analogifremgangsmaade til fremstilling af cycliske aminocarboxylsyrer eller farmakologisk acceptable salte deraf
DK154939C (da) Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf
DK145339C (da) Analogifremgangsmaade til fremstilling af 4-amino-5-hexensyre eller farmaceutisk acceptable salte deraf
DK145119C (da) Analogifremgangsmaade til fremstilling af phenolethere eller syreadditionssalte deraf
DK155943C (da) Analogifremgangsmaade til fremstilling af 7-d-(-)-alfa-amino-alfa-(p-acetoxyphenyl)acetamidocephalosporansyrer
DK157246C (da) Analogifremgangsmaade til fremstilling af n-acylamino-alfa-phenylacetamidocephalosporiner eller farmaceutisk acceptable salte heraf.
DK157138C (da) Fremgangsmaade til fremstilling af 7beta-acylamino-7alfa-alkoxycephalosporiner eller 6beta-acylamino-6alfa-alkoxypenicilliner
DK573475A (da) Fremgangsmade til fremstilling af substituerede phenyleddikesyrer
DK163075A (da) Fremgangsmade til fremstilling af aryloxoheptansyrer
DK149230C (da) Analogifremgangsmaade til fremstilling af 5-benzoyl-6-hydroxy-indan-1-carboxylsyrederivater eller farmaceutisk acceptable salte deraf
DK139724C (da) Analogifremgangsmaade til fremstilling af pyridobenzodiazepinoner eller salte heraf
DK225075A (da) Fremgangsmade til fremstilling af alfa-6--desoxy5-hydroxytetracyclin
DK145263C (da) Analogifremgangsmaade til fremstilling af imidazothiaziner eller farmaceutisk acceptable salte deraf
DK147854C (da) Analogifremgangsmaade til fremstilling af n-(1-benzylpiperid-4-yl)-benzamider
DK159654C (da) Analogifremgangsmaade til fremstilling af aminosyrederivater eller fysiologisk acceptable salte deraf
DK144033C (da) Analogifremgangsmaade til fremstilling af l-3-(3,4-dihydroxy-phenyl)-2-methyl-alanin-peptider eller farmakologisk acceptable salte deraf
DK143278C (da) Analogifremgangsmaade til fremstilling af n-(r-tetrahydrofurfuryl)-noroxymorphon eller syreadditionssalte deraf
DK153759C (da) Analogifremgangsmaade til fremstilling af prostansyrederivater
DK146718C (da) Analogifremgangsmaade til fremstilling af benzobicyklononener
DK143556C (da) Analogifremgangsmaade til fremstilling af substituerede phenylisothiourinstoffer
DK140590B (da) Analogifremgangsmåde til fremstilling af 4-cyclopropylmethylenoxy-3-chlorphenyleddikesyre eller salte heraf.
DK146127C (da) Analogifremgangsmaade til fremstilling af 5-(2-hydroxy-n-propoxy)-4-oxo-8-n-propyl-4h-1-benzopyran-2-carboxylsyre eller salte eller estre deraf
DK185575A (da) Fremgangsmade til fremstilling af salte af poly-alfa-hydroxyacrylsyrer
DK216575A (da) Fremgangsmade til fremstilling af methylaminderivater
DK143752C (da) Analogifremgangsmaade til fremstilling af pyridobenzodiazepinoner eller farmakologisk acceptable salte deraf

Legal Events

Date Code Title Description
PUP Patent expired